Palau Pharma S.A.
Heidi Sisniega. Chief Business Officer
Address: Pol. Ind. Riera de Caldes. Avinguda Camí Reial, 51-57
City: 08184 Palau-solità i Plegamans
Phone: 34 93 863 04 83
Fax: 34 93 864 66 06
Mission and Objectives
Palau is a product-driven biopharmaceutical company focused on the discovery and development of revolutionary and differentiated new medicines that are designed to address the unmet medical needs of patients suffering from inflammatory and autoimmune diseases. Its business strategy consists of developing compounds up to the point of obtaining their proof-of-concept in humans, and then establishing strategic alliances with multinational pharmaceutical companies for their subsequent development and commercialization.
Products/Services, Areas of interest for future collaborations/Alliances
Palau Pharma has a broad portfolio of projects at different stages of development from early discovery to the late clinical stages, including two in the market: a drug-coated coronary stent, ACTIVE®-IRIST®, being commercialized worldwide by Iberhopitex; and CIMALGEX®, a product for the treatment of inflammatory pain in companion animals, being currently marketed in Europe and in the near future in US by Vetoquinol Veterinary Pharmaceuticals. For more information about Palau Pharma’s and its projects, visit our website www.palaupharma.com.
At Palau, partnering plays a strong role in both our business model and our development philosophy. We are actively seeking to establish partnerships with leading biotechnology and pharmaceutical companies for the late stage development and commercialization of our projects beyond Phase II clinical trials.